Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Обзорная статья

Theranostics in nuclear medicine practice

Anna YordanovaDepartment of Nuclear Medicine (Clinical Nuclear Medicine)Elisabeth EppardDepartment of Nuclear Medicine (Radiochemistry)Stefan KürpigDepartment of Nuclear Medicine (Radiochemistry)Ralph A. BundschuhDepartment of Nuclear Medicine (Medical Physics and PET)Stefan SchönbergerDepartment of Paediatric Haematology and OncologyMaria A. González-CarmonaGeorg FeldmannDepartment of Medicine 3, University Hospital Bonn, Bonn, GermanyHojjat AhmadzadehfarDepartment of Nuclear Medicine (Clinical Nuclear Medicine)Markus EsslerDepartment of Nuclear Medicine (Clinical Nuclear Medicine)
OncoTargets and Therapyjournal2017en
ABI

Аннотация

The importance of personalized medicine has been growing, mainly due to a more urgent need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets can help predict if a patient will benefit from a particular treatment. Thanks to the quick development of radiopharmaceuticals and diagnostic techniques, the use of theranostic agents has been continually increasing. In this article, important milestones of nuclear therapies and diagnostics in the context of theranostics are highlighted. It begins with a well-known radioiodine therapy in patients with thyroid cancer and then progresses through various approaches for the treatment of advanced cancer with targeted therapies. The aim of this review was to provide a summary of background knowledge and current applications, and to identify the advantages of targeted therapies and imaging in nuclear medicine practices.

Перевод пока недоступен

Темы

Идентификаторы

Цитирования и источники